60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals was incorporated as a Delaware corporation with a stated mission to develop and commercialize therapies for infectious diseases, specifically those affecting tropical and neglected disease markets. The firm has been publicly active since at least 2009 per regulatory filings, though its founding date is not consistently disclosed. Wealth origin and principal ownership remain private, with no named family office or individual publicly tied to the entity. The company's strategy centers on small-molecule drug discovery and clinical development, with its most advanced candidate being tafenoquine for malaria prevention. 60 Degrees Pharmaceuticals has listed additional pipeline programs for other infectious disease indications (per public filings). The firm has engaged in government contracts, including with the U.S. Department of Defense, and has pursued clinical trial partnerships with academic institutions. Geographic operations focus on the United States, with some clinical work extending to Africa, but no additional offices are confirmed. Team size is not publicly documented; secondary sources suggest fewer than 10 employees (per public record). The firm has no known adjacent vehicles such as foundations or operating companies. In the last 24 months, 60 Degrees Pharmaceuticals received an FDA approval for tafenoquine (Arakoda) for malaria prevention (per the FDA, 2022). The firm's structural differentiator is its small platform and focus on a single lead asset, operating with limited disclosed funding compared to larger biopharma peers. Governance details, succession plans, and investor base are not transparent, positioning the firm as a niche developer reliant on government and partnership support rather than institutional capital.